AN OPEN-LABEL, MULTICENTER PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7296682, A CD25- TARGETING, T-REGULATORY CELL DEPLETING ANTIBODY IN PARTICIPANTS WITH ADVANCED AND/OR METASTATIC SOLID TUMORS
2019-002830-35TUMOR SOLIDO AVANZADO Y / O METASTASICOFundación Jiménez DíazInvestigador: DOGER DE SPEVILLE BERNARD
